Aytu Biopharma Inc

aytubio.com

What Do They Do?

Sells prescription medicines for depression, ADHD, and pediatric allergies through wholesalers and pharmacies.

How Do They Make Money?

Wholesalers and pharmacies buy prescription medicines, and the sale is completed when products are delivered to them.

FY2026 revenue

Who Are Their Customers?

The company sells mainly to U.S. wholesalers and pharmacies through distribution intermediaries, and sells directly to pharmacy customers.

Do Revenues Turn Into Profits?

Not on paper. It lost $14.3M in FY2026, but brought in more cash than it spent: $3.3M of free cash flow.

Operating income, FY2026

−14% of revenue

▲ +6% (Loss) vs FY2025 (−$7.8M, −12%)

Net income, FY2026

−25% of revenue

▲ +5% (Loss) vs FY2025 (−$13.6M, −20%)

Free cash flow, FY2026

6% of revenue

▲ Now profitable vs FY2025 (−$2.2M, −3%)

How Are They Changing?

Shrinking. Revenue fell 40% in 4 years, from $96.7M in FY2022 to $57.6M in FY2026, about 12% a year.

Consumer Health exit The business has shifted from prescription medicines plus consumer health products to a single prescription-pharmaceutical business after winding down and divesting Consumer Health.

EXXUA added The older report described prescription products for ADHD and pediatric conditions; the latest adds EXXUA for adult depression and makes it the centerpiece of commercial efforts.

Clinical development suspended The older report described a development-stage asset whose progress awaited funding; the latest says active clinical development is indefinitely suspended and the asset's rights were transferred.

Who Do They Compete With?

Competes with Granules

Comments